501 filings
6-K
BLRX
Bioline Rx Ltd
18 Jun 24
Current report (foreign)
4:05pm
6-K
BLRX
Bioline Rx Ltd
30 May 24
BioLineRx Announces Clinical Trial Agreement with St. Jude Children’s Research Hospital, Inc. to
7:16am
6-K
BLRX
Bioline Rx Ltd
28 May 24
BioLineRx Reports First Quarter 2024 Financial Results and Recent Corporate
7:11am
6-K
BLRX
Bioline Rx Ltd
24 May 24
BioLineRx Announces Abstract on Pilot Study Data from Phase 2 Combination Clinical Trial
7:05am
6-K
BLRX
Bioline Rx Ltd
17 May 24
BioLineRx Announces Receipt of Nasdaq Minimum Bid Price Notification
5:07pm
6-K
t2692thrbt3y
6 May 24
Current report (foreign)
7:14am
6-K
p58a6lxcl2 ajh6mp
17 Apr 24
BioLineRx Announces Poster Presentation on Apheresis Center Efficiency and CXCR4
7:12am
6-K
rj4vrwhq9b7
10 Apr 24
BioLineRx Accesses Second Tranche of $20 Million Under Previously Announced $40 Million
7:24am
6-K
dg68kx1
1 Apr 24
BioLineRx Announces $6 Million Registered Direct Offering
10:35am
424B5
w98t9zvobff4b w9w
1 Apr 24
Prospectus supplement for primary offering
10:30am
20-F/A
ib2jaysv5axdozfue6
26 Mar 24
Annual report (foreign) (amended)
4:57pm
6-K
ece421bu9a4 r4ed5rd
26 Mar 24
BioLineRx Reports 2023 Financial Results and Recent Corporate
7:06am
6-K
228rf9 g0en
4 Mar 24
BioLineRx Strengthens Intellectual Property Estate with Notice of Allowance for U.S. Patent
7:47am
6-K
x6cn0 kvcu
28 Feb 24
BioLineRx Announces First Patient Dosed in Randomized Phase 2 Combination Clinical Trial
7:08am
6-K
n0ry9ff
16 Feb 24
Current report (foreign)
7:07am
EFFECT
acu9mqcmj0q
8 Jan 24
Notice of effectiveness
12:15am
S-8
orr4u4soz8ci9fg3yn
29 Dec 23
Registration of securities for employees
4:20pm
F-3
u4r02
29 Dec 23
Shelf registration (foreign)
4:15pm
6-K
4tl y68yya2e4z
21 Dec 23
BioLineRx Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating
7:05am